免疫疗法：全球市场

全球免疫疗法市场预计将从 2025 年的 2,607 亿美元成长到 2030 年底的 4,674 亿美元，在预测期（2025-2030 年）内以 12.4% 的复合年增长率成长。

预计北美市场规模将从2025年的1,454亿美元成长到2030年底的2,628亿美元，预测期内（2025-2030年）复合年增长率为12.6%。预计欧洲市场规模将从2025年的607亿美元成长到2030年底的1,035亿美元，预测期间（2025-2030年）复合年增长率为11.2%。

本报告调查了全球免疫疗法市场，并提供了市场概况、市场影响因素和市场机会分析、技术趋势、法律制度、市场规模趋势和预测、按各个细分市场和地区进行的详细分析以及主要企业的概况。

目录

第一章执行摘要

• 市场展望
• 调查范围
• 市场摘要
• 市场动态与成长要素
• 新兴技术
• 细分市场分析
• 区域分析
• 结论

第二章 市场概览

• 概述
• 宏观经济因素分析
• 美国关税对製药业的影响
• 医疗费用
• GDP对製药业的影响
• 波特五力分析

第三章 市场动态

• 市场动态
• 市场驱动因素
• 慢性病发生率不断上升
• 企业研发支出增加
• 政府增加拨款和医药品研究开发费用
• 市场限制
• 免疫疗法药物高成本
• 学名药竞争加剧
• 熟练专业人员短缺
• 市场机会
• 免疫疗法的技术进步
• 免疫疗法的潜力

第四章：监理现状

• 概述
• 美国
• 欧洲
• 亚太地区

第五章 新兴技术与管道分析

• 概述
• 人工智慧和机器学习
• 新兴生物标记
• 基因组编辑和CRISPR
• 管道分析
• 专利分析

第六章 市场区隔分析

• 细分市场分析
• 全球免疫疗法市场按疗法类型划分
• 重点总结
• 单株抗体
• 查核点抑制剂
• 细胞激素
• 其他的
• 全球免疫疗法市场按应用领域划分
• 重点总结
• 癌症
• 自体免疫疾病
• 慢性发炎性呼吸系统疾病
• 地理细分
• 全球免疫疗法市场（按地区划分）
• 重点总结
• 北美洲
• 欧洲
• 亚太地区
• 南美洲
• 中东和非洲

第七章 竞争讯息

• 重点总结
• 竞争格局
• 企业市场占有率分析

第八章 免疫疗法市场的永续性：ESG视角

• ESG简介
• 免疫疗法市场的永续性
• ESG观点
• 环境影响
• 对社会的影响
• 管治影响
• ESG风险评估
• 结论

第九章附录

• 调查方法
• 简称
• 来源
• 公司简介
• ABBVIE INC.
• AMGEN INC.
• ASTRAZENECA
• BRISTOL-MYERS SQUIBB CO.
• F. HOFFMANN-LA ROCHE LTD.
• GILEAD SCIENCES INC.
• GSK PLC.
• JOHNSON & JOHNSON SERVICES INC.
• LILLY
• MERCK & CO.INC.
• NOVARTIS AG
• PFIZER INC.
• SANOFI
• TAKEDA PHARMACEUTICAL CO. LTD.
• TEVA PHARMACEUTICAL INDUSTRIES LTD.
• 新兴企业

The global immunotherapy drugs market is expected to grow from $260.7 billion in 2025 and is projected to reach $467.4 billion by the end of 2030, at a compound annual growth rate (CAGR) of 12.4% during the forecast period of 2025 to 2030.

The North American immunotherapy drugs market is expected to grow from $145.4 billion in 2025 and is projected to reach $262.8 billion by the end of 2030, at a CAGR of 12.6% during the forecast period of 2025 to 2030.

The European immunotherapy drugs market is expected to grow from $60.7 billion in 2025 and is projected to reach $103.5 billion by the end of 2030, at a CAGR of 11.2% during the forecast period of 2025 to 2030.

Report Scope

The current report provides detailed information on immunotherapy drugs. It analyzes the market trends with data from 2024, estimates for 2025 and projections of compound annual growth rates (CAGRs) from 2025 through 2030, including regional markets for immunotherapy drugs. This report highlights the current and future market potential and provides a detailed discussion on the competitive environment. The report will also cover regulatory scenarios, drivers, restraints and opportunities. Additionally, it covers market share data for key companies.

The market in this report is segmented by immunotherapy type into checkpoint inhibitors, monoclonal antibodies (mAbs) and cytokine therapy. MAbs are sub-segmented into naked mAbs, conjugated mAbs and bispecific mAbs. Checkpoint inhibitors are sub-segmented into programmed cell death protein 1 (PD-1), cytotoxic T lymphocyte-associated protein 4 (CTLA-4), programmed cell death ligand 1 (PD-L1) and lymphocyte activation gene 3 (LAG-3).

By application, the market is segmented into cancer, autoimmune diseases and chronic inflammatory diseases.

By region, the market is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa (MEA), and South America. The regional segment will cover a detailed analysis of the U.S., Canada, Mexico, Germany, the U.K., France, Italy, Spain, Japan, China, South Korea, Australia and India. Market data is provided for 2024 the base year, with forecasts for 2025 and a forecast value for 2030.

The report aims to:

• Analyze types of immunotherapies.
• Analyze global market size and segmentation.
• Understand market constraints and drivers.
• Provide detailed market forecasts through 2030.
• Assess market shares, competitiveness and industry structure.
• Identify potential long-term impacts on the immunotherapy drug market.

Report Includes

• 88 data tables and 57 additional tables
• An overview of the global market for immunotherapy drugs
• In-depth analysis of global market trends, featuring historical revenue data for 2022-2024, estimated figures for 2025, and forecasts for 2030, including projections of CAGRs through 2030
• Evaluation of the current market size and revenue growth prospects specific to the immunotherapy drugs, accompanied by a market share analysis by therapy type, application and region
• Description of immunotherapy and combination immunotherapy, and discussion of how it targets cell-mediated adaptive immunity
• Details of checkpoint inhibitors, monoclonal antibodies, interleukins and interferons; and coverage of innovative strategies and new targeted approaches for immunotherapy
• Analysis of the current and future demands in the global immunotherapy drugs, along with a detailed analysis of the competitive environment, market regulations and reimbursement practices
• Analysis of drivers, challenges and opportunities affecting the market's growth
• Coverage of evolving technologies, the current and future market potential, R&D activities, growth strategies, new product pipeline, regulatory framework and reimbursement scenarios, and ESG trends of the market
• Market share analysis of the key companies in the immunotherapy drugs, along with their research priorities, product portfolios, global rankings and the competitive landscape
• Profiles of major companies in industry, including F. Hoffmann-La Roche Ltd., Johnson & Johnson Services Inc., Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, and Sanofi

Table of Contents

Chapter 1 Executive Summary

• Market Outlook
• Scope of Report
• Market Summary
• Market Dynamics and Growth Factors
• Emerging Technologies
• Segmental Analysis
• Regional Analysis
• Conclusion

Chapter 2 Market Overview

• Overview
• Macroeconomic Factor Analysis
• Impact of U.S. Tariffs on the Pharmaceutical Industry
• Healthcare Expenditure
• Impact of GDP on the Pharma Sector
• Porter's Five Forces Analysis
• Bargaining Power of Buyers
• Bargaining Power of Suppliers
• Potential for New Entrants
• Threat of Substitutes
• Competitiveness in the Industry

Chapter 3 Market Dynamics

• Market Dynamics
• Market Drivers
• Increasing Incidence of Chronic Diseases
• Increasing R&D Spending by Market Players
• Rise in Government Funding and Pharmaceutical R&D Spending
• Market Restraints
• High Cost of Immunotherapy Drugs
• Rising Generic Competition
• Lack of Skilled Professionals
• Market Opportunities
• Technological Advances in Immunotherapy
• Potential in Immunotherapy

Chapter 4 Regulatory Landscape

• Overview
• U.S.
• Europe
• Asia-Pacific

Chapter 5 Emerging Technologies and Pipeline Analysis

• Overview
• AI and ML
• Emergent Biomarkers
• Genome Editing and CRISPR
• Pipeline Analysis
• Key Takeaways
• Patent Analysis
• Key Takeaways

Chapter 6 Market Segment Analysis

• Segmentation Breakdown
• Global Market for Immunotherapy Drugs, by Therapy Type
• Key Takeaways
• Monoclonal Antibodies
• Checkpoint Inhibitors
• Cytokines
• Others
• Global Immunotherapy Drug Market, by Application
• Key Takeaways
• Cancer
• Autoimmune Diseases
• Chronic Inflammatory Respiratory Condition
• Geographic Breakdown
• Global Market for Immunotherapy Drugs by Region
• Key Takeaways
• North America
• Europe
• Asia-Pacific
• South America
• Middle East and Africa

Chapter 7 Competitive Intelligence

• Key Takeaways
• Competitive Landscape
• Company Share Analysis

Chapter 8 Sustainability in Immunotherapy Drugs Market: An ESG Perspective

• Introduction to ESG
• Sustainability in the Immunotherapy Drug Market
• ESG Perspective
• Environmental Impact
• Social Impact
• Governance Impact
• ESG Risk Ratings
• Conclusion

Chapter 9 Appendix

• Methodology
• Abbreviations
• Sources
• Company Profiles
• ABBVIE INC.
• AMGEN INC.
• ASTRAZENECA
• BRISTOL-MYERS SQUIBB CO.
• F. HOFFMANN-LA ROCHE LTD.
• GILEAD SCIENCES INC.
• GSK PLC.
• JOHNSON & JOHNSON SERVICES INC.
• LILLY
• MERCK & CO.INC.
• NOVARTIS AG
• PFIZER INC.
• SANOFI
• TAKEDA PHARMACEUTICAL CO. LTD.
• TEVA PHARMACEUTICAL INDUSTRIES LTD.
• Emerging Players in the Immunotherapy Drugs Market

List of Tables

• Summary Table : Global Market for Immunotherapy Drugs, by Region, Through 2030
• Table 1 : Health Expenditure
• Table 2 : Rheumatoid Arthritis: Level 3 Cause, 2021
• Table 3 : Average Price of Immunotherapy
• Table 4 : List of Selected Clinical Trials Studies on Immunotherapy
• Table 5 : List of Selected Recent Patents Related to Immunotherapy Drugs, January 2024-June 2025
• Table 6 : Global Market for Immunotherapy Drugs, by Therapy Type, Through 2030
• Table 7 : Global Market for Monoclonal Antibodies in Immunotherapy Drugs, by Type, Through 2030
• Table 8 : Global Market for Monoclonal Antibodies in Immunotherapy Drugs, by Region, Through 2030
• Table 9 : FDA-Approved Immune Checkpoint Inhibitors, 2022
• Table 10 : Global Market for Checkpoint Inhibitors in Immunotherapy Drugs, by Type, Through 2030
• Table 11 : Global Market for Checkpoint Inhibitors in Immunotherapy Drugs, by Region, Through 2030
• Table 12 : Global Market for Cytokines in Immunotherapy Drugs, by Type, Through 2030
• Table 13 : Global Market for Cytokines in Immunotherapy Drugs, by Region, Through 2030
• Table 14 : Players Investing in Oncolytic Virology
• Table 15 : Approved CAR-T Products, 2017-2025
• Table 16 : Global Market for Other Therapy Types in Immunotherapy Drugs, by Region, Through 2030
• Table 17 : Global Market for Immunotherapy Drugs, by Application, Through 2030
• Table 18 : Global Market for Immunotherapy Drugs in Cancer, by Region, Through 2030
• Table 19 : Global Market for Immunotherapy Drugs in Autoimmune Diseases, by Region, Through 2030
• Table 20 : Global Market for Immunotherapy Drugs in Chronic Inflammatory Respiratory Diseases, by Region, Through 2030
• Table 21 : Global Market for Immunotherapy Drugs in Other Diseases, by Region, Through 2030
• Table 22 : Global Market for Immunotherapy Drugs, by Region, Through 2030
• Table 23 : North American Market for Immunotherapy Drugs, by Therapy Type, Through 2030
• Table 24 : North American Market for Immunotherapy Drugs, by Application, Through 2030
• Table 25 : North American Market for Immunotherapy Drugs, by Country, Through 2030
• Table 26 : U.S. Market for Immunotherapy Drugs, by Therapy Type, Through 2030
• Table 27 : U.S. Market for Immunotherapy Drugs, by Application, Through 2030
• Table 28 : Canadian Market for Immunotherapy Drugs, by Therapy Type, Through 2030
• Table 29 : Canadian Market for Immunotherapy Drugs, by Application, Through 2030
• Table 30 : Mexican Market for Immunotherapy Drugs, by Therapy Type, Through 2030
• Table 31 : Mexican Market for Immunotherapy Drugs, by Application, Through 2030
• Table 32 : European Market for Immunotherapy Drugs, by Therapy Type, Through 2030
• Table 33 : European Market for Immunotherapy Drugs, by Application, Through 2030
• Table 34 : European Market for Immunotherapy Drugs, by Country, Through 2030
• Table 35 : German Market for Immunotherapy Drugs, by Therapy Type, Through 2030
• Table 36 : German Market for Immunotherapy Drugs, by Application, Through 2030
• Table 37 : U.K. Market for Immunotherapy Drugs, by Therapy Type, Through 2030
• Table 38 : U.K. Market for Immunotherapy Drugs, by Application, Through 2030
• Table 39 : French Market for Immunotherapy Drugs, by Therapy Type, Through 2030
• Table 40 : French Market for Immunotherapy Drugs, by Application, Through 2030
• Table 41 : Italian Market for Immunotherapy Drugs, by Therapy Type, Through 2030
• Table 42 : Italian Market for Immunotherapy Drugs, by Application, Through 2030
• Table 43 : Spanish Market for Immunotherapy Drugs, by Therapy Type, Through 2030
• Table 44 : Spanish Market for Immunotherapy Drugs, by Application, Through 2030
• Table 45 : Rest of Europe Market for Immunotherapy Drugs, by Therapy Type, Through 2030
• Table 46 : Rest of Europe Market for Immunotherapy Drugs, by Application, Through 2030
• Table 47 : Recently Approved Immunotherapies in Asian Countries, 2021-2024
• Table 48 : Asia-Pacific Market for Immunotherapy Drugs, by Therapy Type, Through 2030
• Table 49 : Asia-Pacific Market for Immunotherapy Drugs, by Application, Through 2030
• Table 50 : Asia-Pacific Market for Immunotherapy Drugs, by Country, Through 2030
• Table 51 : Chinese Market for Immunotherapy Drugs, by Therapy Type, Through 2030
• Table 52 : Chinese Market for Immunotherapy Drugs, by Application, Through 2030
• Table 53 : Japanese Market for Immunotherapy Drugs, by Therapy Type, Through 2030
• Table 54 : Japanese Market for Immunotherapy Drugs, by Application, Through 2030
• Table 55 : Indian Market for Immunotherapy Drugs, by Therapy Type, Through 2030
• Table 56 : Indian Market for Immunotherapy Drugs, by Application, Through 2030
• Table 57 : South Korean Market for Immunotherapy Drugs, by Therapy Type, Through 2030
• Table 58 : South Korean Market for Immunotherapy Drugs, by Application, Through 2030
• Table 59 : Australian Market for Immunotherapy Drugs, by Therapy Type, Through 2030
• Table 60 : Australian Market for Immunotherapy Drugs, by Application, Through 2030
• Table 61 : Rest of Asia-Pacific Market for Immunotherapy Drugs, by Therapy Type, Through 2030
• Table 62 : Rest of Asia-Pacific Market for Immunotherapy Drugs, by Application, Through 2030
• Table 63 : South American Market for Immunotherapy Drugs, by Therapy Type, Through 2030
• Table 64 : South American Market for Immunotherapy Drugs, by Application, Through 2030
• Table 65 : South American Market for Immunotherapy Drugs, by Country, Through 2030
• Table 66 : Brazilian Market for Immunotherapy Drugs, by Therapy Type, Through 2030
• Table 67 : Brazilian Market for Immunotherapy Drugs, by Application, Through 2030
• Table 68 : Argentine Market for Immunotherapy Drugs, by Therapy Type, Through 2030
• Table 69 : Argentine Market for Immunotherapy Drugs, by Application, Through 2030
• Table 70 : Rest of South America Market for Immunotherapy Drugs, by Therapy Type, Through 2030
• Table 71 : Rest of South America Market for Immunotherapy Drugs, by Application, Through 2030
• Table 72 : MEA Market for Immunotherapy Drugs, by Therapy Type, Through 2030
• Table 73 : MEA Market for Immunotherapy Drugs, by Application, Through 2030
• Table 74 : MEA Market for Immunotherapy Drugs, by Sub-Region, Through 2030
• Table 75 : Middle Eastern Market for Immunotherapy Drugs, by Therapy Type, Through 2030
• Table 76 : Middle Eastern Market for Immunotherapy Drugs, by Application, Through 2030
• Table 77 : African Market for Immunotherapy Drugs, by Therapy Type, Through 2030
• Table 78 : African Market for Immunotherapy Drugs, by Application, Through 2030
• Table 79 : News/Key Developments in the Immunotherapy Drug Market, 2023-2025
• Table 80 : Key Focus Areas in ESG Metrics
• Table 81 : ESG Rankings for Leading Companies in Immunotherapy Drugs Market, 2025*
• Table 82 : Abbreviations Used in this Report
• Table 83 : Report Sources
• Table 84 : AbbVie Inc.: Company Snapshot
• Table 85 : AbbVie Inc.: Financial Performance, FY 2023 and 2024
• Table 86 : AbbVie Inc.: Product Portfolio
• Table 87 : AbbVie Inc.: News/Key Developments, 2023-2025
• Table 88 : Amgen Inc.: Company Snapshot
• Table 89 : Amgen Inc.: Financial Performance, FY 2023 and 2024
• Table 90 : Amgen Inc.: Product Portfolio
• Table 91 : Amgen Inc.: News/Key Developments, 2022-2025
• Table 92 : AstraZeneca: Company Snapshot
• Table 93 : AstraZeneca: Financial Performance, FY 2023 and 2024
• Table 94 : AstraZeneca: Product Portfolio
• Table 95 : AstraZeneca: News/Recent Developments, 2023-2024
• Table 96 : Bristol-Myers Squibb Co.: Company Snapshot
• Table 97 : Bristol-Myers Squibb Co.: Financial Performance, FY 2022 and 2024
• Table 98 : Bristol-Myers Squibb Co.: Product Portfolio
• Table 99 : Bristol-Myers Squibb Co.: News/Key Developments, 2023-2025
• Table 100 : F. Hoffmann-La Roche Ltd.: Company Snapshot
• Table 101 : F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2023 and 2024
• Table 102 : F. Hoffmann-La Roche Ltd.: Product Portfolio
• Table 103 : F. Hoffmann-La Roche Ltd.: News/Key Developments, 2022-2025
• Table 104 : Gilead Sciences Inc.: Company Snapshot
• Table 105 : Gilead Sciences Inc.: Financial Performance, FY 2023 and 2024
• Table 106 : Gilead Sciences Inc.: Product Portfolio
• Table 107 : Gilead Sciences Inc.: News/Key Developments, 2023-2025
• Table 108 : GSK Plc: Company Snapshot
• Table 109 : GSK Plc: Financial Performance, FY 2023 and 2024
• Table 110 : GSK Plc: Product Portfolio
• Table 111 : GSK Plc: News/Key Developments, 2022-2025
• Table 112 : Johnson & Johnson Services Inc.: Company Snapshot
• Table 113 : Johnson & Johnson Services Inc.: Financial Performance, FY 2023 and 2024
• Table 114 : Johnson & Johnson Services Inc.: Product Portfolio
• Table 115 : Johnson & Johnson Services Inc.: News/Key Developments, 2022-2025
• Table 116 : Lilly: Company Snapshot
• Table 117 : Lilly: Financial Performance, FY 2023 and 2024
• Table 118 : Lilly: Product Portfolio
• Table 119 : Lilly: News/Key Development, 2022-2025
• Table 120 : Merck & Co. Inc.: Company Snapshot
• Table 121 : Merck & Co. Inc.: Financial Performance, FY 2023 and 2024
• Table 122 : Merck & Co. Inc.: Product Portfolio
• Table 123 : Merck & Co. Inc.: News/Key Developments, 2021-2025
• Table 124 : Novartis AG: Company Snapshot
• Table 125 : Novartis AG: Financial Performance, FY 2023 and 2024
• Table 126 : Novartis AG: Product Portfolio
• Table 127 : Novartis AG: News/Key Developments, 2022-2024
• Table 128 : Pfizer Inc.: Company Snapshot
• Table 129 : Pfizer Inc.: Financial Performance, FY 2023 and 2024
• Table 130 : Pfizer Inc.: Product Portfolio
• Table 131 : Pfizer Inc.: News/Key Developments, 2022-2025
• Table 132 : Sanofi: Company Snapshot
• Table 133 : Sanofi: Financial Performance, FY 2023 and 2024
• Table 134 : Sanofi: Product Portfolio
• Table 135 : Sanofi: News/Key Developments, 2022-2025
• Table 136 : Takeda Pharmaceutical Co. Ltd.: Company Snapshot
• Table 137 : Takeda Pharmaceutical Co. Ltd.: Financial Performance, FY 2023 and 2024
• Table 138 : Takeda Pharmaceutical Co. Ltd.: Product Portfolio
• Table 139 : Takeda Pharmaceutical Co. Ltd.: News/Key Developments, 2023-2025
• Table 140 : Teva Pharmaceutical Industries Ltd.: Company Snapshot
• Table 141 : Teva Pharmaceutical Industries Ltd.: Financial Performance, FY 2023 and 2024
• Table 142 : Teva Pharmaceutical Industries Ltd.: Product Portfolio
• Table 143 : Teva Pharmaceutical Industries Ltd.: News/Key Developments, 2024- 2025
• Table 144 : Some Emerging Players in the Immunotherapy Drugs Market

List of Figures

• Summary Figure : Global Market Shares of Immunotherapy Drugs, by Region, 2024
• Figure 1 : Porter's Five Forces Analysis of the Immunotherapy Drugs Market
• Figure 2 : Market Dynamics of Immunotherapy Drugs
• Figure 3 : Distribution Share of the Most Frequent Cancer Types in Women*, 2022
• Figure 4 : Distribution Share of the Most Frequent Cancer Types in Men*, 2022
• Figure 5 : Estimated New Cancer Cases and Deaths in the U.S., 2024
• Figure 6 : Companies' R&D Expenditure, by Function, 2022
• Figure 7 : National Cancer Institute Research Funding, 2012-2019
• Figure 8 : Global Pharmaceutical R&D Spending and Growth, 2020-2026
• Figure 9 : Immunotherapy-Related Patents and Publications in the U.S. and China
• Figure 10 : Global Market Shares of Immunotherapy Drugs, by Therapy Type, 2024
• Figure 11 : Global Market Shares of Monoclonal Antibodies in Immunotherapy Drugs, by Type, 2024
• Figure 12 : Global Market Shares of Monoclonal Antibodies in Immunotherapy Drugs, by Region, 2024
• Figure 13 : Global Market Shares of Checkpoint Inhibitors in Immunotherapy Drugs, by Type, 2024
• Figure 14 : Global Market Shares of Checkpoint Inhibitors in Immunotherapy Drugs, by Region, 2024
• Figure 15 : Global Market Shares of Cytokines in Immunotherapy Drugs, by Type, 2024
• Figure 16 : Global Market Shares of Cytokines in Immunotherapy Drugs, by Region, 2024
• Figure 17 : Global Market Shares of Other Therapy Types in Immunotherapy Drugs, by Region, 2024
• Figure 18 : Global Market Shares of Immunotherapy Drugs, by Application, 2024
• Figure 19 : Global Market Shares of Immunotherapy Drugs in Cancer, by Region, 2024
• Figure 20 : Global Market Shares of Immunotherapy Drugs in Autoimmune Diseases, by Region, 2024
• Figure 21 : Global Market Shares of Immunotherapy Drugs in Chronic Inflammatory Respiratory Diseases, by Region, 2024
• Figure 22 : Global Market Shares of Immunotherapy Drugs in Other Diseases, by Region, 2024
• Figure 23 : Global Market Shares of Immunotherapy Drugs, by Region, 2024
• Figure 24 : North American Market Shares of Immunotherapy Drugs, by Therapy Type, 2024
• Figure 25 : North American Market Shares of Immunotherapy Drugs, by Application, 2024
• Figure 26 : North American Market Shares of Immunotherapy Drugs, by Country, 2024
• Figure 27 : U.S. Market Shares of Immunotherapy Drugs, by Therapy Type, 2024
• Figure 28 : U.S. Market Shares of Immunotherapy Drugs Market, by Application, 2024
• Figure 29 : Canadian Market Shares of Immunotherapy Drugs, by Therapy Type, 2024
• Figure 30 : Canadian Market Shares of Immunotherapy Drugs, by Application, 2024
• Figure 31 : Mexican Market Shares of Immunotherapy Drugs, by Therapy Type, 2024
• Figure 32 : Mexican Market Shares of Immunotherapy Drugs, by Application, 2024
• Figure 33 : European Market Shares of Immunotherapy Drugs, by Therapy Type, 2024
• Figure 34 : European Market Shares of Immunotherapy Drugs, by Application, 2024
• Figure 35 : European Market Shares of Immunotherapy Drugs, by Country, 2024
• Figure 36 : German Market Shares of Immunotherapy Drugs, by Therapy Type, 2024
• Figure 37 : German Market Shares of Immunotherapy Drugs, by Application, 2024
• Figure 38 : U.K. Market Shares of Immunotherapy Drugs, by Therapy Type, 2024
• Figure 39 : U.K. Market Shares of Immunotherapy Drugs, by Application, 2024
• Figure 40 : French Market Shares of Immunotherapy Drugs, by Therapy Type, 2024
• Figure 41 : French Market Shares of Immunotherapy Drugs, by Application, 2024
• Figure 42 : Italian Market Shares of Immunotherapy Drugs, by Therapy Type, 2024
• Figure 43 : Italian Market Shares of Immunotherapy Drugs, by Application, 2024
• Figure 44 : Spanish Market Shares of Immunotherapy Drugs, by Therapy Type, 2024
• Figure 45 : Spanish Market Shares of Immunotherapy Drugs, by Application, 2024
• Figure 46 : Rest of Europe Market Shares of Immunotherapy Drugs, by Therapy Type, 2024
• Figure 47 : Rest of Europe Market Shares of Immunotherapy Drugs, by Application, 2024
• Figure 48 : Asia-Pacific Market Shares of Immunotherapy Drugs, by Therapy Type, 2024
• Figure 49 : Asia-Pacific Market Shares of Immunotherapy Drugs, by Application, 2024
• Figure 50 : Asia-Pacific Market Shares of Immunotherapy Drugs, by Country, 2024
• Figure 51 : Chinese Market Shares of Immunotherapy Drugs, by Therapy Type, 2024
• Figure 52 : Chinese Market Shares of Immunotherapy Drugs, by Application, 2024
• Figure 53 : Japanese Market Shares of Immunotherapy Drugs, by Therapy Type, 2024
• Figure 54 : Japanese Market Shares of Immunotherapy Drugs Market, by Application, 2024
• Figure 55 : Indian Market Shares of Immunotherapy Drugs, by Therapy Type, 2024
• Figure 56 : Indian Market Shares of Immunotherapy Drugs Market, by Application, 2024
• Figure 57 : South Korean Market Shares of Immunotherapy Drugs, by Therapy Type, 2024
• Figure 58 : South Korean Market Shares of Immunotherapy Drugs, by Application, 2024
• Figure 59 : Australian Market Shares of Immunotherapy Drugs, by Therapy Type, 2024
• Figure 60 : Australian Market Shares of Immunotherapy Drugs, by Application, 2024
• Figure 61 : Rest of Asia-Pacific Market Shares of Immunotherapy Drugs, by Therapy Type, 2024
• Figure 62 : Rest of Asia-Pacific Market Shares of Immunotherapy Drugs, by Application, 2024
• Figure 63 : South American Market Shares of Immunotherapy Drugs, by Therapy Type, 2024
• Figure 64 : South American Market Shares of Immunotherapy Drugs, by Application, 2024
• Figure 65 : South American Market Shares of Immunotherapy Drugs, by Country, 2024
• Figure 66 : Brazilian Market Shares of Immunotherapy Drugs, by Therapy Type, 2024
• Figure 67 : Brazilian Market Shares of Immunotherapy Drugs, by Application, 2024
• Figure 68 : Argentine Market Shares of Immunotherapy Drugs, by Therapy Type, 2024
• Figure 69 : Argentine Market Shares of Immunotherapy Drugs, by Application, 2024
• Figure 70 : Rest of South America Market Shares of Immunotherapy Drugs, by Therapy Type, 2024
• Figure 71 : Rest of South America Market Shares of Immunotherapy Drugs, by Application, 2024
• Figure 72 : MEA Market Shares of Immunotherapy Drugs, by Therapy Type, 2024
• Figure 73 : MEA Market Shares of Immunotherapy Drugs, by Application, 2024
• Figure 74 : MEA Market Shares of Immunotherapy Drugs, by Sub-Region, 2024
• Figure 75 : Middle Eastern Market Shares of Immunotherapy Drugs, by Therapy Type, 2024
• Figure 76 : Middle Eastern Market Shares of Immunotherapy Drugs, by Application, 2024
• Figure 77 : African Market Shares of Immunotherapy Drugs, by Therapy Type, 2024
• Figure 78 : African Market Shares of Immunotherapy Drugs, by Application, 2024
• Figure 79 : Leading 10 Blockbuster Immunotherapy Drugs, by Sales Revenue, 2023 and 2024
• Figure 80 : Global Market Shares of Immunotherapy Drugs, by Company, 2024
• Figure 81 : Pillars of ESG
• Figure 82 : Advantages of ESG for Companies
• Figure 83 : AbbVie Inc.: Revenue Shares, by Business Unit, FY 2024
• Figure 84 : AbbVie Inc.: Revenue Shares, by Country/Region, FY 2024
• Figure 85 : Amgen Inc.: Revenue Shares, by Business Unit, FY 2024
• Figure 86 : Amgen Inc.: Revenue Shares, by Country/Region, FY 2024
• Figure 87 : AstraZeneca: Revenue Shares, by Business Unit, FY 2024
• Figure 88 : AstraZeneca: Revenue Shares, by Region/Country, FY 2024
• Figure 89 : Bristol-Myers Squibb Co.: Revenue Shares, by Business Unit, FY 2024
• Figure 90 : Bristol-Myers Squibb Co.: Revenue Shares, by Country/Region, FY 2024
• Figure 91 : F. Hoffmann-La Roche Ltd.: Revenue Shares, by Business Unit, FY 2024
• Figure 92 : F. Hoffmann-La Roche Ltd.: Revenue Shares, by Country/Region, FY 2024
• Figure 93 : Gilead Sciences Inc.: Revenue Shares, by Business Unit, FY 2024
• Figure 94 : Gilead Sciences Inc.: Revenue Shares, by Country/Region, FY 2024
• Figure 95 : GSK Plc: Revenue Shares, by Business Unit, FY 2024
• Figure 96 : GSK Plc: Revenue Shares, by Country/Region, FY 2024
• Figure 97 : Johnson & Johnson Services Inc.: Revenue Shares, by Business Unit, FY 2024
• Figure 98 : Johnson & Johnson Services Inc.: Revenue Shares, by Country/Region, FY 2024
• Figure 99 : Lilly: Revenue Shares, by Business Unit, FY 2024
• Figure 100 : Lilly: Revenue Shares, by Country/Region, FY 2024
• Figure 101 : Merck & Co. Inc.: Revenue Shares, by Business Unit, FY 2024
• Figure 102 : Merck & Co. Inc.: Revenue Shares, by Country/Region, FY 2024
• Figure 103 : Novartis AG: Revenue Shares, by Business Unit, FY 2024
• Figure 104 : Novartis AG: Revenue Shares, by Country/Region, FY 2024
• Figure 105 : Pfizer Inc.: Revenue Shares, by Business Unit, FY 2024
• Figure 106 : Pfizer Inc.: Revenue Shares, by Country/Region, FY 2024
• Figure 107 : Sanofi: Revenue Shares, by Country/Region, FY 2024
• Figure 108 : Takeda Pharmaceutical Co. Ltd.: Revenue Shares, by Business Unit, FY 2024
• Figure 109 : Takeda Pharmaceutical Co. Ltd.: Revenue Shares, by Region, FY 2024
• Figure 110 : Teva Pharmaceutical Industries Ltd.: Market Shares, by Country/Region, FY 2024